Hiromichi Ebi
0000-0003-3155-7576
Publication & Citation Trends
Most Cited Works
Publications
237 total
ctDNA-based molecular residual disease and survival in resectable colorectal cancer PDF
Cited by 157
OpenAlex
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition OA
Cited by 4
Semantic Scholar
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition OA
Cited by 3
Semantic Scholar
Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18)
Cited by 7
Semantic Scholar
Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment. OA
Cited by 8
Semantic Scholar
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.
Cited by 0
Semantic Scholar
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS
Cited by 61
Semantic Scholar
First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities OA
Cited by 38
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(97)
Colorectal Cancer Treatments and Studies
(71)
Cancer Genomics and Diagnostics
(41)
PI3K/AKT/mTOR signaling in cancer
(29)
Melanoma and MAPK Pathways
(27)
Frequent Co-Authors
Affiliations
Kanazawa University
Boston University
Brigham and Women's Hospital
Boston Medical Center
Tufts Medical Center